Defunct Company
Total Trials
11
As Lead Sponsor
8
As Collaborator
3
Total Enrollment
2,149
NCT00088166
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
Phase: Phase 3
Role: Lead Sponsor
Start: May 31, 2004
Completion: Mar 31, 2008
NCT00226655
An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies
Start: Jul 31, 2005
Completion: Apr 30, 2009
NCT00226668
XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema
Start: Jan 31, 2006
Completion: Jan 31, 2008
NCT00633321
Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation
Phase: Phase 2
Start: May 31, 2007
Completion: Feb 28, 2009
NCT00691522
Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE)
Role: Collaborator
Start: Nov 30, 2008
Completion: Oct 31, 2009
NCT00820092
Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers
Phase: Phase 1
Start: Dec 31, 2008
NCT01790165
TDT 067 Open Label Multi-Dose Onychomycosis Study
Start: Dec 31, 2009
Completion: Jun 30, 2012
NCT01145807
TDT 067 Onychomycosis Study
Start: Apr 30, 2010
Completion: Aug 31, 2012
NCT01369121
Tolerability Study of Xerecept® in Pediatric Patients
Phase: Phase 1/2
Start: Jun 30, 2010
Completion: Mar 31, 2013
NCT00969878
Multisite Controlled Trial of Cocaine Vaccine
Start: Aug 31, 2010
Completion: Jul 31, 2014
NCT04311489
Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.
Start: Aug 1, 2020
Completion: Nov 30, 2022